A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries (Unknown)
- New search for: Haugh, Margaret
- New search for: Gresset-Bourgeois, Viviane
- New search for: Macabeo, Bérengère
- New search for: Woods, Anne
- New search for: Samson, Sandrine I.
- New search for: Haugh, Margaret
- New search for: Gresset-Bourgeois, Viviane
- New search for: Macabeo, Bérengère
- New search for: Woods, Anne
- New search for: Samson, Sandrine I.
In:
Expert Review of Vaccines
;
16
, 6
;
545-564
;
2017
- Article (Journal) / Electronic Resource
-
Title:A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
-
Contributors:Haugh, Margaret ( author ) / Gresset-Bourgeois, Viviane ( author ) / Macabeo, Bérengère ( author ) / Woods, Anne ( author ) / Samson, Sandrine I. ( author )
-
Published in:Expert Review of Vaccines ; 16, 6 ; 545-564
-
Publisher:
- New search for: Taylor & Francis
-
Publication date:2017-06-03
-
Size:20 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:Unknown
-
Keywords:
-
Source:
Table of contents – Volume 16, Issue 6
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 525
-
Regulating vaccines at the FDA: development and licensure of Zika vaccinesGruber, Marion F. / Krause, Philip R. et al. | 2017
- 529
-
Do microRNAs play a role in the activity of plant-based vaccines?Rosales-Mendoza, Sergio / Salazar-González, Jorge A. et al. | 2017
- 535
-
A bioinformatics roadmap for the human vaccines projectScheuermann, Richard H. / Sinkovits, Robert S. / Schenkelberg, Theodore / Koff, Wayne C. et al. | 2017
- 545
-
A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countriesHaugh, Margaret / Gresset-Bourgeois, Viviane / Macabeo, Bérengère / Woods, Anne / Samson, Sandrine I. et al. | 2017
- 565
-
MTBVAC from discovery to clinical trials in tuberculosis-endemic countriesMarinova, Dessislava / Gonzalo-Asensio, Jesus / Aguilo, Nacho / Martin, Carlos et al. | 2017
- 577
-
Poliovirus vaccination during the endgame: insights from integrated modelingDuintjer Tebbens, Radboud J. / Thompson, Kimberly M. et al. | 2017
- 587
-
New challenges in therapeutic vaccines against HIV infectionLeal, Lorna / Lucero, Constanza / Gatell, Josep M / Gallart, Teresa / Plana, Montserrat / García, Felipe et al. | 2017
- 601
-
Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidateIkegami, Tetsuro et al. | 2017
- 613
-
Pre-clinical and clinical development of the first placental malaria vaccinePehrson, Caroline / Salanti, Ali / Theander, Thor G. / Nielsen, Morten A. et al. | 2017
- 625
-
Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countriesCohen, Robert / Cohen, Jérémie François / Chalumeau, Martin / Levy, Corinne et al. | 2017
- 641
-
Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trialMadhi, Shabir A / Koen, Anthonet / Jose, Lisa / Moreira, Marta / van Niekerk, Nadia / Cutland, Clare / François, Nancy / Ruiz-Guiñazú, Javier / Yarzabal, Juan Pablo / Borys, Dorota et al. | 2017